Chongqing Primary Aldosteronism Study

Study Overview
=================
Brief Summary
-----------------
We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Detailed Description
-----------------
This study will include the subjects of a series of studies on hypertension conducted by our team, including essential hypertension, PA subjects, and establish a large sample database and specimen bank through follow-up and omics analysis.

Official Title
-----------------
Chongqing Primary Aldosteronism Study

Conditions
-----------------
Primary Aldosteronism

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hypertensive patients who completed ARR screening and necessary further tests; Voluntary to sign the informed consent. Exclusion Criteria: patients with severe cardiac, hepatic or renal dysfunction; suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary aldosteronism<br>screened, confirmed and subtyped according to the guidelines. | Other: no intervention<br>* no intervention<br>|
| Essential hypertension<br>screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| numbers of patients who develop cardiovascular events | compare the long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism and essential hypertension | 1-15 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| estimated glomerular filtration rate (eGFR) | Compare the incidence of hypertensive nephropathy between two groups (based on eGFR) | 1-15 years | 
| The incidence of new atrial fibrillation | Compare the occurrence of new atrial fibrillation between patients with primary aldosteronism and essential hypertension | 1-15 years | 
| The incidence of left ventricular hypertrophy | Compare the occurrence of left ventricular hypertrophy between patients with primary aldosteronism and essential hypertension | 1-15 years | 
| the variation of carotid intima-media thickness | Compare the occurrence of the variation of carotid intima-media thickness between patients with primary aldosteronism and essential hypertension | 1-15 years | 
| subgroup analysis of cardiovascular events | Compare the cardiovascular and cerebrovascular risk between unilateral PA and idiopathic bilateral adrenal hyperplasia | 1-15 years | 
| quality of life score | Compare the quality of life between unilateral PA and idiopathic bilateral adrenal hyperplasia by the questionnaire. | 1-15 years | 
| Cardiovascular risk score | To investigate what kind of cardiovascular risk score can better predict cardiovascular risk of PA | 1-15 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary aldosteronism, cardiovascular events, cerebrovascular events